Citius Pharmaceuticals
CTXR | NASDAQ
$0.54
$0.00 (+0.92%)
At close: Nov 16, 2026, 3:59 PM ET
$0.53
-$0.01 (-1.87%)
After-hours:
Nov 16, 2026, 7:53 PM ET
Citius Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Key Executives
| Name | Position |
|---|---|
| Leonard L. Mazur | Co-Founder, Chief Executive Officer, Chairman & Secretary |
| Jaime Bartushak | Chief Business Officer & Chief Financial Officer |
| Alan Lader | Senior Vice President and Head of Clinical Operations & Quality Assurance |
| Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Gary F. Talarico | Executive Vice President of Operations |
| Ilanit Allen | Vice President of Investor Relations & Corporation Communications |
| Kelly Creighton | Executive Vice President of Chemistry, Manufacturing & Controls |
| Myron S. Czuczman | Executive Vice President & Chief Medical Officer |
| Myron Z. Holubiak | Co-Founder & Executive Vice Chairman |
| Nikolas Burlew | Executive Vice President of Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 8-K | Current Report |
| Aug 21, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 10-Q | Quarterly Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 8-K | Current Report |
| Jun 04, 2026 | SC 13D/A | [Amend] Filing |
| Jun 02, 2026 | EFFECT | Filing |
| Jun 01, 2026 | 8-K | Current Report |
| May 22, 2026 | S-3 | Filing |
Citius Pharmaceuticals
| Country | United States |
| IPO Date | Oct 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Leonard L. Mazur |
Contact Details
11 Commerce Drive Cranford,
New Jersey 07016 United States
Stock Details
| Ticker Symbol | CTXR |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001506251 |
| CUSIP Number | 17322U306 |
| ISIN Number | US17322U3068 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CTXR